Drug intelligence / Profile preview

VDA-001

Development stage: Preclinical
Lead developer: viDA Therapeutics
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes

Overview

VDA-001 is a preclinical-stage drug candidate developed by viDA Therapeutics. It acts as a modulator of granzyme B (GRB), an enzyme involved in immune-mediated tissue damage. By modulating GRB activity, VDA-001 aims to address diseases characterized by excessive or dysregulated immune responses, particularly autoimmune and inflammatory conditions. Its primary indication under investigation is bullous pemphigoid, a rare autoimmune blistering skin disease[1]. The drug is classified as an enzyme-based therapy and has not yet entered clinical trials or received regulatory approval[1][2].

Targets

GZMB (Granzyme B)

Beyond the preview

Go deeper on VDA-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VDA-001.

Explore the full profile